Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Código da empresaALDX
Nome da EmpresaAldeyra Therapeutics Inc
Data de listagemMay 02, 2014
CEODr. Todd C. Brady, M.D., Ph.D.
Número de funcionários9
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 02
Endereço131 Hartwell Avenue
CidadeLEXINGTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02421
Telefone17817614904
Sitehttps://www.aldeyra.com/
Código da empresaALDX
Data de listagemMay 02, 2014
CEODr. Todd C. Brady, M.D., Ph.D.
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados